Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria: Results from the Phase3 Pivotal Trials

Luis Felipe Ensina,Jonathan Bernstein,Gordon Sussman,Marcus Maurer,Ana Maria Gimenez-Arnau,Sarabjit Saini, Vineeth Varanasi,Avantika Barve,Eva Hua,Manmath Patekar,Thomas Severin

Journal of Allergy and Clinical Immunology（2023）

引用 0|浏览8

暂无评分

摘要

Ligelizumab improved symptoms in patients with chronic spontaneous urticaria (CSU) in the Phase-2b study. Here, we report the efficacy and safety of ligelizumab (pooled adult data) from the CSU Phase-3 studies.

查看译文

关键词

chronic spontaneous urticaria,ligelizumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要